Health Catalyst (NASDAQ:HCAT) Given New $5.00 Price Target at Stifel Nicolaus

Health Catalyst (NASDAQ:HCAT) had its price target cut by research analysts at Stifel Nicolaus from $10.00 to $5.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “hold” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 20.80% from the stock’s previous close.

Several other research firms also recently commented on HCAT. Canaccord Genuity Group decreased their price target on shares of Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Tuesday, January 21st. Wells Fargo & Company lowered their price target on shares of Health Catalyst from $13.00 to $10.00 and set an “overweight” rating for the company in a research note on Tuesday, January 21st. Piper Sandler cut their price target on shares of Health Catalyst from $12.00 to $8.00 and set an “overweight” rating for the company in a research report on Tuesday, February 11th. Stephens reiterated an “equal weight” rating and issued a $7.00 price objective on shares of Health Catalyst in a report on Thursday. Finally, KeyCorp upgraded Health Catalyst from a “sector weight” rating to an “overweight” rating and set a $9.00 target price for the company in a report on Wednesday, January 8th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $9.55.

Health Catalyst Price Performance

Shares of NASDAQ HCAT traded down $0.80 during trading hours on Thursday, reaching $4.14. 528,697 shares of the stock traded hands, compared to its average volume of 769,911. The company’s 50-day simple moving average is $6.09 and its two-hundred day simple moving average is $7.26. The company has a market capitalization of $251.85 million, a P/E ratio of -3.07 and a beta of 1.34. Health Catalyst has a 52-week low of $3.76 and a 52-week high of $9.24. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32.

Insider Activity

In related news, insider Kevin Lee Freeman sold 7,500 shares of Health Catalyst stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $8.94, for a total value of $67,050.00. Following the sale, the insider now owns 236,950 shares in the company, valued at $2,118,333. The trade was a 3.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, General Counsel Benjamin Landry sold 19,268 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total transaction of $160,309.76. Following the completion of the transaction, the general counsel now owns 72,250 shares of the company’s stock, valued at $601,120. This trade represents a 21.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 87,610 shares of company stock valued at $664,043. Company insiders own 2.50% of the company’s stock.

Institutional Trading of Health Catalyst

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Janney Montgomery Scott LLC bought a new position in shares of Health Catalyst in the 3rd quarter worth approximately $897,000. Fred Alger Management LLC purchased a new stake in Health Catalyst in the third quarter worth $6,858,000. Millrace Asset Group Inc. bought a new position in Health Catalyst in the third quarter worth $1,568,000. Point72 Asset Management L.P. lifted its position in Health Catalyst by 69.4% during the third quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock valued at $4,208,000 after buying an additional 211,805 shares during the period. Finally, Impax Asset Management Group plc boosted its holdings in shares of Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after buying an additional 360,201 shares in the last quarter. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.